Effexor Generic Suppression Antitrust Litigation

Court: United States District Court, District of New Jersey

In re Effexor XR Antitrust Litigation, Case No.: 11-cv-5590

Leadership Position: Plaintiffs’ Executive Committee

WBE is currently serving on the End-Payor Plaintiffs’ Executive Committee in an antitrust class action filed against Wyeth, Inc., among others, involving the antidepressant Effexor XR.  The plaintiffs allege that Wyeth fraudulently obtained a number of method-of-use patents for Effexor XR and engaged in sham litigation against potential generic competitors in an effort to protect the Effexor XR monopoly.  Plaintiffs further allege that Wyeth entered into an anticompetitive, pay-for-delay settlement with Teva, the first generic ANDA filer, in order to forestall generic competition.  As a result of these actions, generic Effexor XR competition was delayed for more than two years.

To view a copy of the consolidated complaint, click here.

News Articles

Plaintiffs Largely Defeat Motion to Dismiss in RICO Lawsuit Against Centene Corporation, Alleging that Centene Defrauds Consumers through Sale of Its Ambetter Health Insurance Plans

On Thursday, May 2, 2024, U.S. District Court Judge Nancy L. Maldonado ruled that Plaintiffs in Havrilla v. Centene Corp. (N.D. Ill.) could proceed on the majority of their claims against ...

WBE Attorneys Named Among Law360 Legal Lions of the Week

WBE attorneys were honored alongside peers and co-counsel this week, as Law360 recognized the firm for successfully defeating motions to dismiss by John Deere in the publication’s Legal Lions of ...

WBE Appointed Interim Co-Lead Counsel in Amazon Tying Scheme Antitrust Lawsuit

On Monday, November 27 2023, U.S. District Judge John H. Chun of the Western District of Washington appointed attorneys from WBE to serve as interim co-lead counsel and consolidated two proposed ...